The guidance cut reflects slower demand in the rehabilitation space and changes to our private label customer relationships. We are not providing gross margin guidance currently. Given our reductions in revenue expectations, we are seeking improved stabilization in the business before considering reinstituting such guidance. SG&A is anticipated to be in the range of 30% to 32% of net sales for the fiscal year.